Levels of serum immunomodulators and alterations with electroconvulsive therapy in treatment-resistant major depression

Código QR

Levels of serum immunomodulators and alterations with electroconvulsive therapy in treatment-resistant major depression

Serkan Zincir,1 Pelin Öztürk,2 Ali Emrah Bilgen,3 Filiz İzci,4 Cihad Yükselir5 1Department of Psychiatry, Gölcük Military Hospital, Kocaeli, 2Psychiatry Clinic, Erenkoy Training and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, 3...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zincir S, Öztürk P, Bilgen AE, İzci F, Yükselir C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	major depression ECT the immune system cytokines Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/db22b26cdbeb40329ffcb90bfda7de6c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Number of Electroconvulsive Therapy Sessions required for Thai Psychiatric Patients: a Retrospective Study
por: Ittasakul P, et al.
Publicado: (2020)

Changes in the Practice of Electroconvulsive Therapy in Poland: A Nationwide Survey Comparing Data Between 2005 and 2020
por: Antosik-Wójcińska AZ, et al.
Publicado: (2021)

The Association Between Hypoxia Improvement and Electroconvulsive Therapy for Major Depressive Disorder
por: Bian Z, et al.
Publicado: (2021)

A review of ketamine’s role in ECT and non-ECT settings
por: Jankauskas V, et al.
Publicado: (2018)

Medication management during electroconvulsant therapy
por: Zolezzi M
Publicado: (2016)

The level of IL-6 was associated with sleep disturbances in patients with major depressive disorder
por: Wang M, et al.
Publicado: (2019)

Pioglitazone could induce remission in major depression: a meta-analysis
por: Colle R, et al.
Publicado: (2016)

Atrophic Corpus Callosum Associated with Altered Functional Asymmetry in Major Depressive Disorder
por: Ran S, et al.
Publicado: (2020)

The ratio and interaction between neurotrophin and immune signaling during electroconvulsive therapy in late-life depression
por: Dore Loef, et al.
Publicado: (2021)

Evaluation of cognitive impairment in patients with major depressive disorder in remission
por: Mustafa Ali, et al.
Publicado: (2021)

Risk Assessment of Electroconvulsive Therapy in Clinical Routine: A 3-Year Analysis of Life-Threatening Events in More Than 3,000 Treatment Sessions
por: Vivien L. Hajak, et al.
Publicado: (2021)

Prevalence and Predictors of Postictal Confusion After Electroconvulsive Therapy
por: Ittasakul P, et al.
Publicado: (2021)

Investigating the Role of Leukocyte Telomere Length in Treatment-Resistant Depression and in Response to Electroconvulsive Therapy
por: Claudia Pisanu, et al.
Publicado: (2021)

Functional impairment in patients with major depressive disorder: the 2-year PERFORM study
por: Hammer-Helmich L, et al.
Publicado: (2018)

Serum Exosome-Derived miR-139-5p as a Potential Biomarker for Major Depressive Disorder
por: Liang JQ, et al.
Publicado: (2020)

Weighted Gene Coexpression Network Analysis Identifies Specific Modules and Hub Genes Related to Major Depression
por: Zhang G, et al.
Publicado: (2020)

Electroconvulsive therapy in 77-year-old patient with pacemaker: a case report
por: Mędrala T, et al.
Publicado: (2018)

Identification of Gene Co-Expression Modules and Core Genes Related to Immune Disorders in Major Depression Disorder
por: Zhang L, et al.
Publicado: (2021)

Sex differences in gut microbiota in patients with major depressive disorder
por: Chen JJ, et al.
Publicado: (2018)

Shared Genetic Liability and Causal Associations Between Major Depressive Disorder and Cardiovascular Diseases
por: Fuquan Zhang, et al.
Publicado: (2021)

The Combination of Serum BDNF, Cortisol and IFN-Gamma Can Assist the Diagnosis of Major Depressive Disorder
por: Chen S, et al.
Publicado: (2021)

Prevalence of major depressive disorder among hemodialysis patients compared with healthy people in Japan using the Structured Clinical Interview for DSM-IV
por: Tomita T, et al.
Publicado: (2016)

Predictors of Major Depressive Disorder in Older People
por: Susana Sousa, et al.
Publicado: (2021)

Stimulus intensity determined by dose-titration versus age-based methods in electroconvulsive therapy in Thai patients
por: Ittasakul P, et al.
Publicado: (2019)

Association of Serum Kynurenine Levels and Neural Networks in Patients with First-Episode, Drug-Naïve Major Depression: A Source-Based Morphometry Study
por: Okamoto N, et al.
Publicado: (2020)

Electroacupuncture plus moxibustion for major depressive disorder: A randomized, sham-controlled, pilot clinical trial
por: Mikyung Kim, et al.
Publicado: (2022)

Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study
por: Hashimoto T, et al.
Publicado: (2015)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017)

Plasma complement component 4 increases in patients with major depressive disorder
por: Wei J, et al.
Publicado: (2017)

Association between anxious distress in a major depressive episode and bipolarity
por: Sugawara H, et al.
Publicado: (2019)

Elevated peripheral blood glutamate levels in major depressive disorder
por: Inoshita M, et al.
Publicado: (2018)

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
por: Yoshimura R, et al.
Publicado: (2017)

Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study
por: Harada E, et al.
Publicado: (2017)

Assessment of current clinical practices for major depression in Japan using a web-based questionnaire
por: Hori H, et al.
Publicado: (2019)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
por: Harada E, et al.
Publicado: (2016)

Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
por: Saragoussi D, et al.
Publicado: (2018)

Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients
por: Roulot M, et al.
Publicado: (2018)

Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
por: Naghmeh Nikkheslat
Publicado: (2021)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
por: Huang Q, et al.
Publicado: (2016)

Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
por: McIntyre RS, et al.
Publicado: (2021)